Abstract:BRAFV600E mutation is highly prevalent in patients with papillary thyroid carcinoma (PTC), and TERT promoter (TERTp) mutation is strongly associated with cancer-related mortality. However, predictive power of the two mutations remains inconclusive. We aimed to verify the prognostic effects of both mutations to assess the value of mutation detection for risk stratification in terms of PTC prognosis and tumour invasion, to guide PTC diagnosis and treatment. We conducted a literature search in the MEDLINE (PubMed), EMBASE, Web of Science and CENTRAL (Cochrane library) databases, from inception to February 2020. Basic characteristics, prognoses and clinicopathological features were collected from the included studies for further analysis. Twelve studies involving 4184 PTC patients were enrolled in our analysis. In total, 2412 (57.6%) of the patients carried either BRAFV600E or TERTp mutation, and 290 (6.9%) patients had both mutations. TERTp mutation was more common in patients with BRAFV600E mutation (RR = 1.75 [95% CI 1.44-2.13]). Patients with both mutations had a worse prognosis compared with those with a single mutation (vs BRAFV600E only: RR = 5.34 [4.20-6.78] vs TERTp only: RR = 2.12 [1.41-3.19]). TERTp mutation alone independently increased the risk of a poor prognosis (RR = 2.90 [1.93-4.35]) in terms of mortality (RR = 15.09 [7.75-29.37]), disease persistence (RR = 4.00 [2.03-7.90]), recurrence (RR = 4.34 [4.20-6.78]), lymph node metastasis (RR = 1.57 [1.24-1.99]) and distant metastasis (RR = 2.94 [1.13-7.65]). We found that PTC patients with BRAFV600E mutation were more likely to have TERTp mutation. TERTp mutation was an independent predictive factor for poor prognosis of PTC patients, but the predictive value of BRAFV600E mutation remains inconclusive. Patients with both mutations have remarkably higher risks of adverse outcomes compared with those with a single mutation. PTC patients could benefit from mutation detection for aiding risk stratification (BRAF + TERT+ > BRAF - TERT+ > BRAF + TERT-).

TERTPromoter Mutations and Their Association Withbrafv600e Mutation and Aggressive Clinicopathological Characteristics of Thyroid Cancer

TERT Promoter Mutations and Their Association with BRAF V600E Mutation and Aggressive Clinicopathological Characteristics of Thyroid Cancer.

Association of Telomerase Reverse Transcriptase Promoter Mutations with Clinicopathological Features and Prognosis of Thyroid Cancer: a Meta-Analysis.

Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer.

The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas

TERT promoter Mutation and Its Association with Clinicopathological Features and Prognosis of Papillary Thyroid Cancer: A Meta-analysis

Suspicious Ultrasound and Clinicopathological Features of Papillary Thyroid Carcinoma Predict the Status of TERT Promoter

The Role of TERT Promoter Mutations in Postoperative and Preoperative Diagnosis and Prognosis in Thyroid Cancer.

TERT promoter mutations contribute to adverse clinical outcomes and poor prognosis in radioiodine refractory differentiated thyroid cancer

Clinicopathological significance of TERT promoter mutation in papillary thyroid carcinomas: a systematic review and meta-analysis.

Clinical and Histopathological Features of Thyroid Cancer with TERT Promoter Molecular Alterations in Isolation Versus with Concurrent Molecular Alterations: A Multicenter Retrospective Study

Research progress of BRAFV600E and TERT promoter mutations coexistence in papillary thyroid cancer

TERT promoter mutations and additional molecular alterations in thyroid fine-needle aspiration specimens: A multi-institutional study with histopathologic follow-up

The Predictive Value Of Coexisting Brafv600e And Tert Promoter Mutations On Poor Outcomes And High Tumour Aggressiveness In Papillary Thyroid Carcinoma: A Systematic Review And Meta-Analysis

Relationship Between BRAFV600E Gene and TERT Promoter Mutations with Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma

Clinicopathological Significance of TERT Promoter Mutation in Papillary Thyroid Carcinomas: a Systematic Review and Meta‐analysis

Correlation Between TERT C228T and Clinic-Pathological Features in Pediatric Papillary Thyroid Carcinoma

TERT mutations and aggressive histopathologic characteristics of radioiodine-refractory papillary thyroid cancer

Clinical features combined with ultrasound characteristics to predict TERT promoter mutations in papillary thyroid carcinoma: a single-center study over the past 5 years

TERT Promoter Mutations Increase Tumor Aggressiveness by Altering TERT mRNA Splicing in Papillary Thyroid Carcinoma

BRAF-induced EHF expression affects TERT in aggressive papillary thyroid cancer